Trial Profile
An open-label positron emission tomography study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing advanced or metastatic breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Pharmacokinetics; Registrational
- 24 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 19 Jul 2011 New trial record